The present invention relates generally to medical devices, kits and methods used for improved healing of skin after a therapeutic injury. For example, such devices, kits and methods can be used to produce improved tightening of skin after a therapeutic treatment. The devices, kits and methods can also be used to produce a temporary cosmetic effect by displacing skin to stimulate a clinical effect.
Many procedures involve producing a therapeutic injury to tissue to produce an improved therapeutic or cosmetic effect in the tissue. Skin tightening is one such therapy that involves creating an injury to produce an improved cosmetic appearance of the skin near or around the site of the therapeutic injury. Skin tightening can be performed many different ways ranging from invasive treatments to less invasive procedures such as IPL (intense pulsed light). Typically invasive procedures appear to be the most effective but require significant recuperative periods, while less invasive procedures are less effective than invasive procedures but the recuperative periods are shorter. In any case, the healing process that occurs subsequent to the therapeutic injury can determine the effectiveness of the procedure.
Again, in referring to skin tightening as one example, during the procedure a physician or medical practitioner induces a controlled trauma in the skin. This is typically performed by applying energy to the tissue to either ablate (vaporize) or non-ablatively heat the skin to create either patterns of lesions or a localized area of treatment. There are limits when creating therapeutic injury to tissue, if there is variability in the lesion or hole created in the tissue the healing process may not produce the optimal effect. For example, if the therapeutic treatment creates openings in the tissue that are too large, the tissue may not heal as desired.
In one variation, a skin treatment system is provided, comprising an dressing with a load per millimeter width of at least 0.1 Newtons at a strain of at least 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or higher, and a limiting member coupled to the dressing and configured to resist straining of the dressing beyond a predetermined strain. The limiting member may comprise a first handle at a first end of the at least one limiting member, and a second handle at a second end of the at least one limiting member. The skin treatment system may comprise at least two elongate strain limiting structures. The first handle may be contiguously or non-contiguously coupled to the dressing between the first ends of the at least two elongate strain limiting structures. The second handle may also be contiguously or non-contiguously coupled to the dressing between the second ends of the at least two elongate strain limiting structures. The predetermined strain may be at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or higher. The limiting member may be releasably coupled to the dressing. The limiting member may be adhered to the dressing using an adhesive. The adhesive may comprise a shear-resistance to a force level that is greater than the T-peel resistance to the force level. The first handle and the second handle may comprise a substantially inelastic material relative to the dressing, which may optionally be a semi-rigid or rigid material. The limiting member may comprise at least one flexible, inelastic elongate element. The dressing may comprise an unstrained configuration in which a distance between a first attachment region of the limiting member and a second attachment region of the limiting member is less than a length of the limiting member between the first attachment region and the second attachment region, and may comprise a strained configuration at the predetermined strain wherein the distance between the first attachment region of the limiting member and a second attachment region of the limiting member is substantially equal to the a length of the limiting member between the first attachment region and the second attachment region. The limiting member may comprise a folded board with at least three two folds, or a ratchet and pawl mechanism. The limiting member may be selectively configured to resist straining of the dressing beyond a plurality of predetermined strains. The plurality of predetermined strains may comprise graphical indicia on the limiting member.
In another variation, the skin treatment system comprises an dressing, comprising a tensioning axis, and a limiting member coupled to the dressing and configured to resist straining of the dressing beyond a predetermined strain, wherein the attachment of a first end of the limiting member to the dressing is contiguous across a dimension of the dressing transverse to the tensioning axis. The dressing may have a load per millimeter width of at least 0.1 Newtons at a strain of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or higher. The limiting member may comprise a first handle at a first end of the at least one limiting member, and a second handle at a second end of the at least one limiting member. The skin treatment system may comprise at least two elongate strain limiting structures. The first handle may be contiguously coupled to the dressing between the first ends of the at least two elongate strain limiting structures. The second handle may also be contiguously coupled to the dressing between the second ends of the at least two elongate strain limiting structures. The predetermined strain may be at least 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or higher. The limiting member may be releasably coupled to the dressing. The limiting member may be adhered to the dressing using an adhesive. The adhesive may comprise a shear-resistance to a force level that is greater than the T-peel resistance to the force level. The first handle and the second handle may comprise a substantially inelastic material relative to the dressing, which may optionally be a semi-rigid or rigid material. The limiting member may comprise at least one flexible, inelastic elongate element. The dressing may comprise an unstrained configuration in which a distance between a first attachment region of the limiting member and a second attachment region of the limiting member is less than a length of the limiting member between the first attachment region and the second attachment region, and may comprise a strained configuration at the predetermined strain wherein the distance between the first attachment region of the limiting member and a second attachment region of the limiting member is substantially equal to the a length of the limiting member between the first attachment region and the second attachment region. The limiting member may comprise a folded board with at least three two folds, or a ratchet and pawl mechanism. The limiting member may be selectively configured to resist straining of the dressing beyond a plurality of predetermined strains. The plurality of predetermined strains may comprise graphical indicia on the limiting member.
In another variation, a skin treatment system is provided, comprising an elastic structure, first and second handles attached to opposite regions of the elastic structure, wherein the first and second handles are coupled to the elastic structure and configured to provide a substantially uniform tensile force across the elastic structure; and a strain indicator. The strain indicator may comprises graphical or numerical indicia of the degree of strain.
In one variation, a skin treatment device is provided, comprising a first layer comprising an elastic material prestretched to a predetermined strain level and a second layer coupled to the first layer and comprising a brace configured to maintain the first layer at the predetermined strain level while the device is attached to a skin layer of a subject; and comprising at least one second layer opening positionable for treatment of skin therethrough, and a securing element configured to secure the device to skin of a subject during treatment through said at least one second layer opening. The first layer may comprise at least one elastic material opening through the elastic material configured to be aligned with the at least one opening of the second layer for treatment through the aligned openings. The brace may further comprise a mating element configured to secure the first layer in a strained configuration on the brace. The brace may be rigid. The brace may comprise a plurality of segments bendable with respect to another of the plurality of segments to provide a variable contour of the brace. The brace may be configured to be bendable in a plurality of directions. Each of the plurality of segments may be configured to be bent in a plurality of directions. The second layer may comprise a mask having a pattern of openings. The pattern of openings comprises a treatment pattern. The skin treatment device may further comprise a connection element configured to connect the device to an energy emitting skin treatment device. Each second layer opening may correspond to at least one individual treatment zone. The second layer may be removable from the first layer after treatment is provided through the at least one second layer opening.
In another variation, a multilayered elastic dressing is provided, comprising a plurality of elastic layers, wherein each layer removably coupled to another layer of said plurality of elastic layers; wherein said plurality of elastic layers comprises a base layer having a skin adhesive layer on a skin adhesive side of the base layer and at least one additional layer. Each said at least one additional elastic layer may be removable from the base layer after the dressing has been strained and adhered to skin of a subject to thereby selectively alter the stresses placed on the skin through the base layer.
In another variation, a method of treating a subject is provided, comprising creating a plurality of lesions on a subject's skin and placing a dressing over the lesions on the subject's skin.
In another variation, a method treating a subject is provided, comprising placing a dressing over a skin region and creating lesions in the skin region through the dressing. Creating lesions in the skin regions may be performed using an energy-based modality. The dressing may comprise a mask region configured to selectively block the energy-based modality and a treatment region configured to selectively permit energy from the energy-based modality to pass through the dressing. The treatment region comprises an uninterrupted structure configured to selectively permit energy to pass through the uninterrupted structure. The uninterrupted structure may be an optically clear structure. The method may further comprise aligning a treatment device to indicia located on the dressing. The method may further comprise aligning a treatment device to pre-existing openings in the dressing. The pre-existing openings may be pre-existing potential openings in the dressing. The pre-existing potential openings may comprise slits. The method may further comprise creating a plurality of openings in the dressing using a treatment device.
In another variation, a method of treating a subject is provided, comprising maintaining a strain in an elastic dressing, placing the strained dressing over skin of a subject, creating at least one lesion on the skin of the subject through the dressing; and then releasing the dressing so that compressive forces from the dressing are applied to the skin of the subject.
A need remains for devices, kits and/or procedures to improve the outcome of such medical procedures by improving the healing process of the tissue subsequent to the treatment.
The methods, procedures, kits, and devices described herein are intended to assist with the healing process of tissue that was previously or simultaneously treated for a therapeutic or cosmetic effect. Assisting in the healing process can produce an improved outcome and in some cases can eliminate or reduce variability with the healing process. The combined therapeutic process of treating tissue and assisting the ensuing healing process can produce a consistent skin tightening procedure and improve the outcome of the procedure. It is noted that combinations of variations of the methods, kits, and/or procedures as well as combination of specific aspects of methods, kits, and/or procedures are within the scope of this disclosure even though such embodiments may not be specifically shown.
U.S. Pat. No. 7,683,234 to Gurtner et al describes devices and methods intended for the amelioration of scar and/or keloid formation and include a discussion of wound healing as well other information that can be combined with the novel methods, devices, and kits of the present invention. Accordingly, the entirety of this reference is incorporated by reference herein.
The present disclosure describes the methods, procedures, kits, and devices for use with skin tightening, treatment of skin laxity, skin contraction, skin shrinkage, and maybe even body sculpting procedures for purposes of illustration. However, the invention is not limited to skin tightening unless specifically noted otherwise. The benefits of the present disclosure can be applied in any number of medical procedures requiring providing augmentation of the healing process of a therapeutic or cosmetic treatment. For example, the devices herein may be used for sutureless wound closure, skin splinting or other supportive uses. Other uses for these skin treatment devices may or may not include without limitation, for example, amelioration or prevention of scar formation, treating skin related conditions such as acne, blemishes, rosacea, warts, rashes (including but not limited to erythematous, macular, papular and/or bullous conditions), psoriasis, skin irritation/sensitivity, allodynia, telangiectasia, port wine stains and other arterio-venous malformations, and ectopic dermatitis; treating or improving existing scars, wrinkles, stretch marks, loose or sagging skin or other skin irregularities; lifting, pinning, holding, moving skin for various purposes such as during pre-operative preparation, during surgical procedures for example as a low-profile tissue retractor, to stabilize blood vessels during needle or catheter insertion, postoperatively, pre or post operatively for pre-treating or preconditioning skin for example, prior to scar revision, wound incision, body contouring, in mastectomy skin expansion, during weight loss, or for aesthetic purposes; hair removal or hair loss; treating and/or closing skin injuries for example, incisions, wounds, chronic wounds, bed sores, ulcers (including venous stasis ulcers), preventing or reducing the incidence of wound dehiscence, diabetic skin or wound conditions, burn healing and/or relief; acting as an occlusive or negative-pressure wound dressing; protecting incisions or wounds, e.g. prevention of splitting or opening, protecting newborn belly buttons after cutting umbilical cord. Such treatments may include use of a drug or other therapeutic agent that may be applied to the skin with such device. The agents may include but are not limited to antibiotics, anti-fungals, immune modulators including corticosteroids and non-steroidal immune modulators. The agents may be provided in any of a variety of formulations, including but not limited powders, gels, lotions, creams, pastes, suspensions, etc. The devices may also be used for purposes of delivering a drug to the skin or through the skin, for example by stretching the skin and applying a drug thereto. Different configurations of the device may be amenable to the size or geometry of different body regions. The treatments may be applied to regions of any shape (e.g. linear, curved, stellate), size or depth, and to one or more regions of the body, including but not limited to the scalp, forehead, face (e.g. nose, eyelid, cheeks, lips, chin), ears, neck, shoulder, upper arm, lower arm, palm, dorsum of the hand, fingers, nailbed, axilla, chest, nipple, areola, back, abdomen, inguinal region, buttocks, perineal region, labia, penis, scrotum, thigh, lower leg, plantar surface of the foot, dorsal surface of the foot, and/or toes.
A number of procedures for tightening of skin are commonly known. One non-invasive approach involves the use of laser energy to ablate (vaporize) or non-ablatively heat the skin. Ablative procedures are generally more invasive (i.e. longer down time) and effective. These types of lasers do not produce consistent skin tightening, and presently none of these lasers are FDA indicated for skin tightening. In general, the procedure relies on a lesion (if an area is treated) or a number of lesions to heal after the injury to produce a tightened appearance in or around the skin that was treated. However, if the holes or lesion made by the treatment device are too large, the skin surface will not heal well. In addition, the procedure might not produce an optimal outcome if the healing process is not consistent between the lesions. Furthermore, care must be taken to prevent environmental factors from interfering with the healing process. Additionally many non-ablative tightening procedures rely on collagen contraction to produce volume changes in the collagen by a thermal denaturation process that produces dimensional changes in skin in one or more axes. See, for example, the RF product THERMAGE® (Solta Corp., Hayward, Calf.) or the IR product TITAN® (Cutera, Inc., Brisbane, Calif.). The devices herein may also be used with other skin treatments (aesthetic or not) or resurfacing procedures whether topical or subdermal, whether or not using an energy modality such as, for example, microwave, radio-frequency ablation, high-intensity focused ultrasound, laser, infrared, incoherent light, thermal (heat and/or cold, ablative or non-ablative), use of vacuum or suction, vibration or massage (e.g. ENDERMOLOGIE®, LPG Systems, France). The methods, kits, and devices described herein can optionally be used with such non-ablative tightening procedures as well. For example, a water jet can be used to create lesions by directing water or other liquid, and/or a mix of liquid and particles to create the lesions. Furthermore, the water or fluid can be used to swell or expand tissue. Once expanded the tissue can be treated such that upon reversion to a normal non-swelled state, the tissue engages in natural compression.
In conventional skin tightening procedures, there is variability in the healing phase of the dermis 10. This variability can lessen the desired cosmetic effect. The dressings described herein are intended to reduce this variability and provide an improved effect as a result of the healing process.
The device can be placed on the dermis 10 as shown in
In those variations where the dressing 100 is elastomeric and pre-stretched, the release of the dressing 100 from the stretching force creates the closure force F that is applied on tissue. In alternate variations, the dressing 100 can provide a closure force via thermal, electrical, chemical or other activation of an appropriately configured dressing 100. In such cases, the dressing applies little or no force unless activated.
As shown above, the dressing 100 can have openings adjacent to the lesion 14.
The openings may have any of a variety of shapes, including circles, ovals, triangles, square, rectangular, star-shaped, etc. Each of the In some variations, the openings (or a portion of the openings) may comprise potential openings which appear to be slits or cuts in the dressing, which then open or spread apart upon tensioning.
In some further variations, one or more of the openings may be reinforced with a thicker or non-elastic material to reduce or control excessive strain in the dressing material about the openings, in comparison to regions without openings. In some variations, the reinforcement may comprise open or closed perimeter, ring-like structures surrounding the openings. Materials that may be used for the reinforcement structures include but are not limited to low-density polyethylene (LDPE), fluorinated ethylene propylene (FEP) or nylon. The openings 108 of the dressing 100 may comprise individual reinforcement structures 124, as depicted in
The dressing 100 can be retained on the skin by any number of mechanisms. For example, some variations include an adhesive located between the skin and dressing. Alternate variations include the use of a tape or other sealing means placed around or at edges of the dressing 100. The use of mechanical fasteners, e.g., staples, sutures, etc. is also within the scope of this disclosures.
Any of the dressings 100 shown above (and/or braces) can be mated or aligned with the lesion-creating device so that the dressing can be applied with a single device. Alternatively, a number of dressings 100 can be fitted to the treatment device in a cartridge-like form so that the physician can position a dressing onto the treatment device prior to application of the device to tissue.
For example, the physician can create lesions aligned to a directional path that is similar to sutures that could be used to tighten the tissue.
In another variation, a dressing 100 can be adhered to tissue or skin without significantly stretching and then is stretched. Stretching the tissue in this manner uniformly and gently stretches the skin underlying the dressing in a direction along Langer's lines along with the dressing.
When the skin is then treated through the dressing in a stretched condition, releasing the stretch as well as removing the dressing will allow a gentle closure force due to the skin's own natural elasticity. Presently, physicians stretch tissue using their fingers to stretch the tissue area as they treat. However, this process increases overall procedure time since the physician is only able to treat small areas at any given time. A variation of present invention includes a dressing that is stretched after being applied to the skin to stretch the skin along Langer's lines. Once the tissue is treated, the dressing is removed. This permits the natural resiliency of the skin to provide a gentle closure force without having to leave the dressing in place.
In many cases, the dressings described herein are intended for positioning on contoured tissue surfaces rather than planar surface. Accordingly, there may be a need to provide a dressing that can approximate the contoured shape prior to affixing to the tissue surface.
In additional variations, a frame can be used without a dressing to apply strain to the tissue in a similar manner as a dressing. For example, a deformable frame can apply a compression force to the tissue and then can be affixed to the tissue in a manner as described herein (e.g., adhesive, mechanical fasteners, sutures, etc.) Doing so allows the frame itself to compress tissue to assist healing of the treated region.
The dressings of the present invention can also provide temporary results to simulate a clinical effect. These temporary results can allow a patient or physician to determine the type or amount of treatment desired. For example, a physician can position pre-strained dressings on a patient to show the patient the results of a procedure given a pre-determined amount of shrinkage or lift. Such a feature allows a physician to position dressings having a pre-determined amount of strain on a patient so that the patient can visually see the results of the given reduction. For example, a physician can position dressings that lift the skin by a given amount so that the patient can determine whether more or less lift is desired. The goal is to simulate clinical results and allow a patient to see a real time simulated clinical result via the application of the dressings. Such pre-strained dressings can be provided as a kit having varying ranges of displacement with corresponding templates to assist the physician in applying apply therapeutic treatments to match the temporary state of the tissue. In this way, a patient can observe the simulated clinical result, once a desired result is achieved; the physician can select treatment templates based on the dressings that are used to produce the temporary effect. Use of the dressings to simulate a clinical effect can be used in any number of cosmetic procedures outside of skin tightening. In additional variations, the simulated clinical effect can be used to establish a treatment plan. Such a treatment plan can include the amount of or location where the therapeutic treatment. The simulated clinical effect can be processed through a computer analysis to provide the physician with a treatment plan based on the type of dressing used or amount of lift used to produce acceptable or desired results.
In additional variations a dressing can be used to limit the lesion size or to minimize collateral damage to tissue. For example, a solid dressing can be applied to tissue as described above. Next, a laser can then be used to create openings in the dressing as well as to create the lesion. For instance, an Er:YAG laser or an Er:YsGG may be used with a Cr2+:or CR2t:ZnSe Q-switching device, or a Cr2+:Cr2t:ZnS Q-switching device to apply a pulse in a Q switched mode followed by a free running mode or normal mode. The pulse could be used to remove a portion of the dressing since the pulse produces a plasma initiation and expansion to photomechanically remove the layer of the dressing (e.g., a silicone layer). The free running mode operation creates a micro lesion via photothermal ablation of the tissue.
The above system or configuration allows for a skin tightening therapy with an adhesive patch applied to skin with the skin and patch ablated in situ. The patch is applied to untreated skin under tension with an adhesive. The patch initially does not have holes over the areas where lesions are to be formed. The entire patch may be solid or may have holes or other features to position and/or stretch the patch. An initial laser beam ablates holes or other features in the patch to expose certain areas of the skin. The exposed areas can then be treated through holes in the patch. The laser parameters are such that the patch material is cleanly ablated with a minimum of thermal damage to the underlying skin. A second laser beam of possibly different character is then used to ablate a controlled amount of skin. An additional benefit of creating openings in the dressing and subsequently creating lesions is that the lesion pattern and/or openings in the dressing can be customized during a procedure rather than needing to follow the pattern of a pre-configured dressing.
One benefit of creating openings in the dressing in situ is that there is no need for orienting a dressing having pre-made openings with previously created lesions. Yet another benefit of creating openings in-situ is that the pattern or features of the holes in the dressing are customized to match the lesions.
Once the system obtains feedback regarding the registration features, the system can confirm that the treatment device is in the correct position. Subsequently, image analysis hardware and software can be used to recognize the patterns or openings 108 in the dressing 100 to either control the treatment parameters, to maintain a database of treatment areas, or to perform some other custom treatment depending upon type of dressing or orientation of the dressing.
One approach is to position a handheld scanning handpiece directed at the approximate location of the treatment. The system can determine whether positioning of the handpiece is within an acceptable tolerance using an optical detection of one or more registration features 202, 204. Once the system confirms correct or acceptable positioning, the system can then permit or trigger a treatment cycle. For example, a laser scan pattern can be released on a time scale sufficiently rapid enough (<50 msec) such that inadvertent motion of the handheld scanning handpiece does not appreciably affect the pattern. The handheld scanning handpiece can be repositioned to treat the next zone, and the optical detection of registration features at the correction positioning of the dressing with respect to the handpiece will again trigger the release of a laser scan pattern.
Alternatively, a handpiece with either scanning patterns or fixed patterns (including a single shot) can be manually positioned laterally to the dressing, with optical detection of the registration features 202, 204 triggering individual firing events. One example involves the use of an optical mouse-type arrangement in which a light source such as an LED projects onto the dressing surface and the reflected or scattered light from the dressing is re-imaged into an optical detector as the handheld device is manually moved laterally across the dressing.
Alternatively, a complete image may be acquired by an imaging system, and image-processing software may be used to create a custom scan pattern to be delivered. The positioning of the dressing with respect to the laser delivery system, the particular configuration of the dressing, the desired pattern of lesions may all be processed to determine a customized laser scanning pattern appropriate for a particular dressing and patient. In this realization, a relatively large area may be treated by a scanned laser pattern, which may require a duration that is long enough that movements of the patient with respect to the laser delivery device may occur. The invention may interrupt delivery of laser pulses is motion of the registration features 202, 204 is detected. The positioning may be restored and laser firing resumed. Alternatively, a new image may be acquired and a new laser delivery pattern computed and delivered.
Elastomeric dressings of the present disclosure can also be used by affixing to the tissue, stretching or straining once placed on tissue. Then creating the lesions in the tissue. The dressing can then be released to compress the lesion. The dressing can also be removed so that the natural elasticity of the skin or tissue helps appose the lesion openings. Accordingly, the dressing can be removed.
In additional variations, the dressings or frames described herein can be affixed to external structures placed on a patient to provide the degree of lift or tissue movement required for an acceptable clinical effect. For example, a cap or similar structure can be placed on a patient's head and serve an anchoring type device that allows the dressings or frames to displace tissue for an acceptable simulated visual result.
The devices, methods and kits described herein can be used for applying force to any portion of tissue to compress, reposition, or lift tissue as required by the intended cosmetic application (e.g., lifting of the breast, stretching scalp tissue to increase a density of implanted, underarm, abdominal procedures, etc. The dressing described herein can be fabricated from any biocompatible material that can provide the compressive force necessary to achieve
the intended result. For example, the dressings can comprise a polymer, a shape memory polymer (e.g., acrylate-based, styrene-based and epoxy-based shape memory polymers), or biocompatible polymer (e.g., silicone). The dressings and/or frame can be transparent or opaque or have other features as required by the intended application. The strain rates of the dressings and frames described herein can range from 1% to 100% either uni-directional, uni-axial, or bi-axial.
The fixation means described above can include any conventionally known means to secure similar dressings or frames to tissue. For example, the devices can be secured to tissue in a variety of ways (either temporarily affixed or affixed until the fixation means is removed). For example, the devices can be removably secured to the tissue with an adhesive, with a skin piercing device, or the like. Suitable adhesives include pressure sensitive adhesives, such as polyacrylatebased, polyisobutylene-based, temperature activated adhesives, chemically activated adhesives and silicone-based pressure sensitive adhesives. Suitable skin-piercing devices include clamps, needles, microneedles, sutures, anchors, staples, microtines and the like.
The devices may have any suitable or desirable shape or size. In some examples, the shape of the dressings or frames can be adjusted before, during or after the procedure. For example, the devices may have a shape selected from the group consisting of rectangles, circles, squares, trapezoids, toroids, ovals, or segments and combinations thereof. For example, some devices may be substantially circular, others may be substantially toroidal, and still others may be substantially rectangular.
In another aspect, altering the geometry of a lesion to assist in wound healing can be combined with methods and devices described herein to improve the outcome of a treatment. For example,
The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.
This application is a continuation of U.S. application Ser. No. 13/411,443, filed on Mar. 2, 2012, which claims benefit under 35 U.S.C. § 119(e) to a) U.S. Provisional Application Ser. No. 61/448,809, filed on Mar. 3, 2011, b) U.S. Provisional Application Ser. No. 61/476,163, filed on Apr. 15, 2011, and c) U.S. Provisional Application Ser. No. 61/605,717, filed on Mar. 1, 2012, all of which are hereby incorporated by reference in their entirety. This application is also related to U.S. application Ser. No. 11/888,978, filed on Aug. 3, 2007, U.S. application Ser. No. 12/854,859, filed on Aug. 11, 2010, and U.S. application Ser. No. 13/345,524, filed Jan. 6, 2012, all of which are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
114750 | Battersby | May 1871 | A |
363538 | Penny | May 1887 | A |
633050 | Spenard | Sep 1899 | A |
1074413 | Baun et al. | Sep 1913 | A |
1774489 | David | Aug 1930 | A |
1969188 | Spicer | Aug 1934 | A |
2018517 | Edward | Oct 1935 | A |
2303131 | Morgan | Nov 1942 | A |
2371978 | Perham | Mar 1945 | A |
2421193 | James | May 1947 | A |
2472009 | James | May 1949 | A |
2714382 | Solis | Aug 1955 | A |
2722220 | Mestrand | Nov 1955 | A |
2762371 | Guio | Sep 1956 | A |
3103218 | Ajemian | Sep 1963 | A |
3402716 | Baxter | Sep 1968 | A |
3487836 | Niebel et al. | Jan 1970 | A |
3528426 | Vukojevic | Sep 1970 | A |
3575782 | Hansen | Apr 1971 | A |
3613679 | Bijou | Oct 1971 | A |
3645835 | Hodgson | Feb 1972 | A |
3698395 | Hasson | Oct 1972 | A |
3863640 | Haverstock | Feb 1975 | A |
3926193 | Hasson | Dec 1975 | A |
3933158 | Haverstock | Jan 1976 | A |
3983878 | Kawchitch | Oct 1976 | A |
4038989 | Romero-sierra et al. | Aug 1977 | A |
4073298 | Le | Feb 1978 | A |
4114624 | Haverstock | Sep 1978 | A |
4141363 | James et al. | Feb 1979 | A |
4173131 | Melton et al. | Nov 1979 | A |
4222383 | Schossow | Sep 1980 | A |
4282005 | Sato et al. | Aug 1981 | A |
4346700 | Dunshee et al. | Aug 1982 | A |
4370981 | Sanderson | Feb 1983 | A |
4413621 | Mccracken et al. | Nov 1983 | A |
4423731 | Roomi | Jan 1984 | A |
4425176 | Shibano et al. | Jan 1984 | A |
4447482 | Heinzelman et al. | May 1984 | A |
4496535 | Gould et al. | Jan 1985 | A |
4531521 | Haverstock | Jul 1985 | A |
4535772 | Sheehan | Aug 1985 | A |
4539990 | Stivala | Sep 1985 | A |
4549653 | Lauritzen | Oct 1985 | A |
4598004 | Heinecke | Jul 1986 | A |
4605005 | Sheehan | Aug 1986 | A |
4646731 | Brower | Mar 1987 | A |
4653492 | Parsons | Mar 1987 | A |
4696301 | Barabe | Sep 1987 | A |
4699133 | Schaefer et al. | Oct 1987 | A |
4702251 | Sheehan | Oct 1987 | A |
4706661 | Barrett | Nov 1987 | A |
4732146 | Fasline et al. | Mar 1988 | A |
4742826 | Mclorg | May 1988 | A |
4753232 | Ward | Jun 1988 | A |
4780168 | Beisang et al. | Oct 1988 | A |
4787381 | Hubbard et al. | Nov 1988 | A |
4807613 | Koehnke et al. | Feb 1989 | A |
4815457 | Mazars et al. | Mar 1989 | A |
4815468 | Annand | Mar 1989 | A |
4825866 | Pierce | May 1989 | A |
4881546 | Kaessmann | Nov 1989 | A |
4915102 | Kwiatek et al. | Apr 1990 | A |
4917929 | Heinecke | Apr 1990 | A |
4924866 | Yoon | May 1990 | A |
4950282 | Beisang et al. | Aug 1990 | A |
RE33353 | Heinecke | Sep 1990 | E |
4984584 | Hansen et al. | Jan 1991 | A |
5011492 | Heimerl et al. | Apr 1991 | A |
5026389 | Thieler | Jun 1991 | A |
5047047 | Yoon | Sep 1991 | A |
5058579 | Terry et al. | Oct 1991 | A |
5066299 | Bellingham | Nov 1991 | A |
5106629 | Cartmell et al. | Apr 1992 | A |
5127412 | Cosmetto et al. | Jul 1992 | A |
5176703 | Peterson | Jan 1993 | A |
5234462 | Pavletic | Aug 1993 | A |
5259835 | Clark et al. | Nov 1993 | A |
5263970 | Preller | Nov 1993 | A |
5333753 | Etheredge | Aug 1994 | A |
5383900 | Krantz | Jan 1995 | A |
5507775 | Ger et al. | Apr 1996 | A |
5520762 | Rasmussen et al. | May 1996 | A |
5522879 | Scopelianos | Jun 1996 | A |
5545713 | Krejci et al. | Aug 1996 | A |
5549713 | Kim | Aug 1996 | A |
5552162 | Lee | Sep 1996 | A |
5562705 | Whiteford | Oct 1996 | A |
5628724 | Debusk et al. | May 1997 | A |
5649960 | Pavletic | Jul 1997 | A |
5662624 | Sundstroem et al. | Sep 1997 | A |
5662714 | Charvin et al. | Sep 1997 | A |
5662717 | Burns | Sep 1997 | A |
5713842 | Kay | Feb 1998 | A |
5723009 | Frechet et al. | Mar 1998 | A |
5758662 | Hall | Jun 1998 | A |
5759560 | Dillon | Jun 1998 | A |
5779659 | Allen | Jul 1998 | A |
5885254 | Matyas | Mar 1999 | A |
5891076 | Fabo | Apr 1999 | A |
5919476 | Fischer et al. | Jul 1999 | A |
5931800 | Rasmussen et al. | Aug 1999 | A |
5947998 | Cartmell et al. | Sep 1999 | A |
5998694 | Jensen et al. | Dec 1999 | A |
6007564 | Haverstock | Dec 1999 | A |
6043406 | Sessions et al. | Mar 2000 | A |
6093465 | Gilchrist et al. | Jul 2000 | A |
6120525 | Westcott | Sep 2000 | A |
6255552 | Cummings et al. | Jul 2001 | B1 |
6264976 | Heinecke et al. | Jul 2001 | B1 |
6284941 | Cox et al. | Sep 2001 | B1 |
6297420 | Heincke | Oct 2001 | B1 |
6297423 | Schoenfeldt et al. | Oct 2001 | B1 |
6343224 | Parker | Jan 2002 | B1 |
6346653 | Sessions et al. | Feb 2002 | B1 |
6410818 | Oyaski | Jun 2002 | B1 |
6469066 | Dosch et al. | Oct 2002 | B1 |
6472581 | Muramatsu et al. | Oct 2002 | B1 |
6485503 | Jacobs et al. | Nov 2002 | B2 |
6495230 | Do | Dec 2002 | B1 |
6570051 | Beaudry | May 2003 | B1 |
6572878 | Blaine | Jun 2003 | B1 |
6573419 | Naimer | Jun 2003 | B2 |
6634653 | Chatterjea | Oct 2003 | B2 |
6726696 | Houser et al. | Apr 2004 | B1 |
6759481 | Tong | Jul 2004 | B2 |
6822133 | Lebner | Nov 2004 | B2 |
6831205 | Lebner | Dec 2004 | B2 |
6870074 | Gilman | Mar 2005 | B2 |
6986855 | Hood et al. | Jan 2006 | B1 |
7066182 | Dunshee | Jun 2006 | B1 |
7066934 | Kirsch | Jun 2006 | B2 |
7100615 | Kert | Sep 2006 | B1 |
7122712 | Lutri et al. | Oct 2006 | B2 |
7135606 | Dozier et al. | Nov 2006 | B1 |
7227050 | Sigurjonsson et al. | Jun 2007 | B2 |
7332641 | Lebner et al. | Feb 2008 | B2 |
7354446 | Lebner | Apr 2008 | B2 |
7414168 | Lebner | Aug 2008 | B2 |
7456332 | Beaudry | Nov 2008 | B2 |
7511185 | Lebner | Mar 2009 | B2 |
7563941 | Lebner et al. | Jul 2009 | B2 |
7683234 | Gurtner et al. | Mar 2010 | B2 |
7834232 | Rastegar et al. | Nov 2010 | B2 |
RE42126 | Ye et al. | Feb 2011 | E |
8063263 | Gurtner et al. | Nov 2011 | B2 |
8168850 | Gurtner et al. | May 2012 | B2 |
8183428 | Gurtner et al. | May 2012 | B2 |
8389791 | Gurtner et al. | Mar 2013 | B2 |
8395011 | Zepeda et al. | Mar 2013 | B2 |
8592640 | Zepeda et al. | Nov 2013 | B2 |
8674164 | Zepeda et al. | Mar 2014 | B2 |
9248048 | Jackson et al. | Feb 2016 | B2 |
9248051 | Gurtner et al. | Feb 2016 | B2 |
9358099 | Naor et al. | Jun 2016 | B2 |
9492329 | Zepeda et al. | Nov 2016 | B2 |
20020013300 | Capelli-schellpfeffer | Jan 2002 | A1 |
20020193723 | Girardin et al. | Dec 2002 | A1 |
20030014053 | Nguyen et al. | Jan 2003 | A1 |
20030040687 | Boynton et al. | Feb 2003 | A1 |
20030092969 | Omalley et al. | May 2003 | A1 |
20030220700 | Hammer et al. | Nov 2003 | A1 |
20050033215 | Lebner | Feb 2005 | A1 |
20050034731 | Rousseau et al. | Feb 2005 | A1 |
20050070956 | Rousseau | Mar 2005 | A1 |
20050080453 | Lebner et al. | Apr 2005 | A1 |
20050095275 | Zhu et al. | May 2005 | A1 |
20050095276 | Kartheus et al. | May 2005 | A1 |
20050125051 | Eidenschink et al. | Jun 2005 | A1 |
20050245966 | Hammerslag et al. | Nov 2005 | A1 |
20050274453 | Anvar | Dec 2005 | A1 |
20050283141 | Giovannoli | Dec 2005 | A1 |
20060009099 | Jonn et al. | Jan 2006 | A1 |
20060020235 | Siniaguine | Jan 2006 | A1 |
20060037091 | Gurtner et al. | Feb 2006 | A1 |
20060246802 | Hughes et al. | Nov 2006 | A1 |
20060282135 | Tankovich | Dec 2006 | A1 |
20070032845 | Neuberger | Feb 2007 | A1 |
20070093161 | Eede et al. | Apr 2007 | A1 |
20070129776 | Robins et al. | Jun 2007 | A1 |
20070142761 | Aali | Jun 2007 | A1 |
20070191752 | Lebner | Aug 2007 | A1 |
20070239232 | Kurtz et al. | Oct 2007 | A1 |
20070239236 | Manstein | Oct 2007 | A1 |
20070282235 | Beaudry | Dec 2007 | A1 |
20070282374 | Sogard et al. | Dec 2007 | A1 |
20080033334 | Gurtner | Feb 2008 | A1 |
20080051687 | Rogers | Feb 2008 | A1 |
20080172047 | Altshuler | Jul 2008 | A1 |
20080208098 | Rennix | Aug 2008 | A1 |
20080228220 | Weiser | Sep 2008 | A1 |
20080269658 | Vinton | Oct 2008 | A1 |
20090131845 | Gurtner et al. | May 2009 | A1 |
20090131846 | Gurtner et al. | May 2009 | A1 |
20090163844 | Gurtner et al. | Jun 2009 | A1 |
20090177136 | Liedtke et al. | Jul 2009 | A1 |
20100191253 | Oostman, Jr. et al. | Jul 2010 | A1 |
20100280428 | Widgerow et al. | Nov 2010 | A1 |
20110152738 | Zepeda et al. | Jun 2011 | A1 |
20110319798 | Digrazia | Dec 2011 | A1 |
20120035521 | Zepeda et al. | Feb 2012 | A1 |
20120046586 | Gurtner et al. | Feb 2012 | A1 |
20120046590 | Yock et al. | Feb 2012 | A1 |
20120046591 | Gurtner et al. | Feb 2012 | A1 |
20120083724 | Zepeda et al. | Apr 2012 | A1 |
20120203273 | Riskin et al. | Aug 2012 | A1 |
20120221044 | Archibald et al. | Aug 2012 | A1 |
20120226214 | Gurtner et al. | Sep 2012 | A1 |
20120226306 | Jackson et al. | Sep 2012 | A1 |
20130012858 | Jackson et al. | Jan 2013 | A1 |
20130184629 | Gurtner et al. | Jul 2013 | A1 |
20130190673 | Gurtner et al. | Jul 2013 | A1 |
20130281904 | Jackson et al. | Oct 2013 | A1 |
20140088481 | Jackson et al. | Mar 2014 | A1 |
20140135677 | Zepeda et al. | May 2014 | A1 |
20140135678 | Zepeda et al. | May 2014 | A1 |
20160213522 | Gurtner et al. | Jul 2016 | A1 |
20170020522 | Yock | Jan 2017 | A1 |
Number | Date | Country |
---|---|---|
2010282523 | Apr 2012 | AU |
2321491 | Sep 1999 | CA |
2621387 | Mar 2007 | CA |
2659772 | Feb 2008 | CA |
1414842 | Apr 2003 | CN |
1608604 | Apr 2005 | CN |
101563113 | Oct 2009 | CN |
201481501 | May 2010 | CN |
102665623 | Sep 2012 | CN |
2161011 | Mar 2010 | EP |
2464322 | Jun 2012 | EP |
2424584 | Oct 2006 | GB |
2004515256 | May 2004 | JP |
2004223087 | Aug 2004 | JP |
2004536898 | Dec 2004 | JP |
2006513748 | Apr 2006 | JP |
2007531578 | Nov 2007 | JP |
2007537781 | Dec 2007 | JP |
2009545382 | Dec 2009 | JP |
2013501591 | Jan 2013 | JP |
20080007084 | Jan 2008 | KR |
20100094700 | Aug 2010 | KR |
20100129958 | Dec 2010 | KR |
20140020993 | Feb 2014 | KR |
2019138 | Sep 1994 | RU |
1997017919 | May 1997 | WO |
1997030700 | Aug 1997 | WO |
1997030700 | Aug 1997 | WO |
2000053139 | Sep 2000 | WO |
2001039693 | Jun 2001 | WO |
2002015816 | Feb 2002 | WO |
2002015816 | Feb 2002 | WO |
2002045698 | Jun 2002 | WO |
2002045698 | Jun 2002 | WO |
2002087645 | Nov 2002 | WO |
2002092783 | Nov 2002 | WO |
2002092783 | Nov 2002 | WO |
2004060413 | Jul 2004 | WO |
2004073567 | Sep 2004 | WO |
2005079674 | Sep 2005 | WO |
2005096979 | Oct 2005 | WO |
2005096981 | Oct 2005 | WO |
2005096981 | Mar 2006 | WO |
2006124671 | Nov 2006 | WO |
2006124671 | Apr 2007 | WO |
2008019051 | Feb 2008 | WO |
2008019051 | Apr 2008 | WO |
2011019859 | Feb 2011 | WO |
2011019859 | Apr 2011 | WO |
2012094648 | Jul 2012 | WO |
2012119131 | Sep 2012 | WO |
Entry |
---|
English translation of Decision for Patent Grant for KR Application No. 10-2013-7026319, dated Oct. 14, 2019. |
English translation of Decision to Grant a Patent for JP Application No. 2017-192700, dated May 8, 2020. |
English translation of KR Office Action for Application No. 10-2020-7001161, dated Mar. 18, 2020. |
English translation of Notice of Final Rejection for JP Application No. 2017-192700, dated Nov. 19, 2019. |
English translation of BR Office Action for Application No. 1120130225254, dated Sep. 18, 2019. |
English translation of CN Office Action for Application No. 201810545618.4, dated Jul. 3, 2020. |
English Translation of Decision to Grant received in KR App. No 10-2020-7001161 dated Sep. 4, 2020. |
“NHSSB Wound Management Manual”, Northern Health and Social Services Board, 2005, pp. 1-97. |
3M Healthcare, “3M™ Steri-Strip™ Adhesive Skin Closures (Reinforced): Commonly Asked Questions”, 3M Healthcare, St. Paul, MN, Jun. 27, 2002, pp. 1-4. |
3M Healthcare, “3M™ Steri-Strip™ S Surgical Skin Closure Application Examples, Comparisons, and Results”, 3M Healthcare St. Paul, MN, 2007, 4 pages. |
3M Healthcare, “3M™ Steri-Strip™ S Surgical Skin Closure Patient Care Information”, 3M Healthcare, St. Paul, MN, 2006, 2 pages. |
3M Healthcare, “3M™ Steri-Strip™ S Surgical Skin Closure The Simple, Non-Invasive Alternative to Staples and Sutures from the Steri-Strip Family”, 3M Healthcare, St. Paul, MN, 2006, 2 pages. |
3M Healthcare, “3M™ Steri-Strip™ S Surgical Skin Closure”, 3M Healthcare, St. Paul, MN, 1 page. |
3M Healthcare, “3M™ Steri-Strip™ S Surgical Skin Closure. Application Instructions”, 3M Healthcare, 2007, 2 pages. |
3M Healthcare, “3M™ Steri-Strip™ S Surgical Skin Closure Commonly Asked Questions”, 3M Healthcare, St. Paul, MN, Oct. 19, 2006, pp. 1-8. |
3M Healthcare, “3M™ Steri-Strip™ Surgical Skin Closure Poster of Available Sizes”, 3M Healthcare, St. Paul, MN, 3 pages. |
3M Healthcare, “Reducing the Risk of Superficial Skin Damage Related to Adhesive Use”, 3M Healthcare, St. Paul, MN, 2001, 2 pages. |
3M Healthcare, “Steri-Strip: Skin Closures”, Product Insert, 3M Healthcare, St. Paul, MN 2003, 1 page. |
3M Healthcare, “They Say Every Scar Tells a Story”, 3M Healthcare, St. Paul, MN, 2006, 1 page. |
3M Healthcare, “Tips for Trouble-Free Taping”, 3M Healthcare, St. Paul, MN, May 2004, 4 pages. |
3M Healthcare, 3M™ Steri-Strip™ S Surgical Skin Closure Application Instructions, 3M Healthcare, St. Paul, MN, 2007, 2 pages. |
Anonymous, “3M™ Steri-Strip™ Adhesive Skin Closures”, 3M Brochure, 2003, 12 pages. |
Anonymous, “3M™ Tegaderm™ Family of Transparent Dressings”, 3M Brochure, 2005, 6 pages. |
Anonymous, “Avocet Polymet Technologies, Inc.”, available online at <http:/www.avocetcorp.com/index.html>, last visited on Nov. 5, 2007, 2 pages. |
Anonymous, “Avogel Scar Hydrogel,”, available online at <http://avocetcorp.com/avogel_scar_hydrogel.html>, last visited on Nov. 5, 2007, 1 page. |
Anonymous, “Avosil Ointment”, available online at <http://www.avocetcorp.com/avosil.html>, last visited on Nov. 5, 2007, 3 pages. |
Anonymous, “Mepiform Instructions of Use”, Tendra Corporation Brochure, 2 pages. |
Anonymous, “Silicone Scar Bandage: Standard Wound Healing Application”, available online at <http://www.thejamushop.com/silicon_sheet_for_keloids.htm>, last visited on Mar. 18, 2009, 4 pages. |
Brace, “Definition of Brace”, Merriam Webster, Available Online at <www.merriam-webster.com>, 2015, 4 pages. |
Canica Design Inc., “ABRA Abdominal Wall Closure Set: A Dynamic Wound Closure System”, Instructions for Use, available online at <http://www.canica.com/instructions/1D1544%20ABRA%20CWK08.pdf>, last visited on Sep. 10, 2009, pp. 1-11. |
Canica Design Inc., “ABRA Surgical Skin Closure Set: A Dynamic Wound Closure System”, available online at <http://www.canica.com/instructions/1D0830.pdf>, last visited on Sep. 10, 2009, pp. 1-4. |
Decision for Grant received for Korean Patent Application No. 10-2009-7003220, dated May 14, 2014, 3 pages. |
Decision for Grant received for Korean Patent Application No. 10-2014-7005383, dated Dec. 10, 2014, 3 pages. |
Decision of Grant Received for Chinese Patent Application No. 201280012003.6, dated Feb. 3, 2015, 2 pages. |
English Translation of Notice Grounds for Preliminary Rejection dated Feb. 8, 2019 for Korean application No. 10-2013-7026319. |
English Translation of First Office Action dated Apr. 2, 2019 for Japanese application No. 2017-192700. |
Extended European Search Report (includes Supplementary European Search Report and Search Opinion) received for European Patent Application No. 12752239.9, dated Oct. 1, 2014, 7 pages. |
Extended European Search Report and European Search Opinion received for European Patent Application No. 10808724.8, dated Aug. 19, 2013, 8 pages. |
International Preliminary Report on Patentability received for PCT Application No. PCT/US2013/025449, dated Feb. 5, 2015, 7 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2007/017320, dated Feb. 3, 2009, 8 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2010/045239, dated Feb. 23, 2012, 10 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/020561, dated Jul. 18, 2013, 8 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/025510, dated Aug. 29, 2013, 10 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/027618, dated Sep. 12, 2013, 12 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2007/017320, dated Feb. 7, 2008, 10 pages. |
International Search Report and Written Opinion Received for PCT Patent Application No. PCT/US2010/045239, dated Feb. 8, 2011, 12 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2012/020561, dated May 1, 2012, 9 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2012/025510, dated May 29, 2012, 11 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2012/027618, dated Jun. 28, 2012, 11 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/25449, dated Apr. 23, 2013, 7 pages. |
Mask, “Definition of Mask”, Merriam Webster, Available Online at <www.merriam-webster.com>, 2015, 4 pages. |
Notice of Acceptance Received for Australian Patent Application No. 2010282523, dated Jul. 2, 2015, 2 pages. |
Notice of Allowance received for Israel Patent Application No. 218020, dated Dec. 11, 2014, 4 pages. |
Notice of Allowance received for Japanese Patent Application No. 2009-522879, dated Mar. 17, 2014, 6 pages. |
Notice of Allowance received for Japanese Patent Application No. 2012-524855, dated Apr. 30, 2015, 3 pages. |
Notice of Allowance received for Japanese Patent Application No. 2013-037053, dated Jan. 6, 2015, 3 pages. |
Office Action received for Australian Patent Application No. 2010282523, dated May 6, 2014. |
Office Action received for Australian Patent Application No. 2012204174, dated Aug. 4, 2015, 2 pages. |
Office Action received for Canadian Patent Application No. 2,659,772, dated Oct. 30, 2013, 3 pages. |
Office Action received for Canadian Patent Application No. 2,659,772, dated Sep. 11, 2014, 2 pages. |
Office Action received for Chinese Patent Application No. 201080045471.4, dated Sep. 29, 2013, 4 pages. |
Office Action received for Chinese Patent Application No. 201080045471.4, dated May 21, 2014, 6 pages. |
Office Action received for Chinese Patent Application No. 2012280021431.5 dated Jul. 17, 2015, 4 pages. |
Office Action received for Chinese Patent Application No. 201280012003.6, dated Jun. 30, 2014, 9 pages. |
Office Action received for Chinese Patent Application No. 201280021431.5, dated Sep. 22, 2014, 3 pages. |
Office Action received for Chinese Patent Application No. 201310474149.9, dated Jan. 27, 2015, 10 pages. |
Office Action received for Chinese Patent Application No. 201310474149.9, dated Jul. 27, 2015, 6 pages. |
Office Action received for European Patent Application No. 07836471.8, dated Jul. 13, 2010, 7 pages. |
Office Action received for European Patent Application No. 10808724.8, dated Jan. 15, 2015, 4 pages. |
Office Action received for Indian Patent Application No. 654/DELNP/2009, dated Jul. 31, 2014, 4 pages. |
Office Action received for Israeli Patent Application No. 218020, dated Dec. 1, 2013, 12 pages. |
Office Action Received for Japanese Patent Application No. 2012-524855, dated Apr. 14, 2014, 7 pages. |
Office Action received for Japanese Patent Application No. 2012-524855, dated Oct. 24, 2014, 5 pages. |
Office Action received for Japanese Patent Application No. 2013-037053, dated Mar. 17, 2014, 5 pages. |
Office Action received for Japanese Patent Application No. 2013548594, dated Jul. 7, 2015, 10 pages. |
Office Action Received for Japanese Patent Application No. 2014-123100, dated May 18, 2015, 1 page. |
Office Action received for Japanese Patent Application No. 2014-143959, dated May 1, 2015, 2 pages. |
Office Action received for Korean Patent Application No. 10-2009-7003220, dated Oct. 28, 2013, 6 pages. |
Office Action Received for Korean Patent Application No. 10-2014-7005383, dated May 14, 2014, 6 pages. |
Shanghai Dongyue Medical Health Product Co., Ltd., “Silicon-gel Membrane-Scar Bandage”, available online at <http://shdongyue.com/cp/shaos/shaos02b.asp>, last visited on Nov. 6, 2008, 2 pages. |
Smith & Newphew, “CICA-CARE* Silicone Gel Sheeting”, available online at <http://wound.smith-nephew.com/za/Product.asp?NodeId=569&Tab=5&Hide=True>, last visited on Jun. 9, 2009, 1 page. |
Wound Care Technologies, “DERMAClose™ RC: Continuous External Tissue Expander”, available online at <http://www.woundcaretech.com/sell-sheet.pdf>, last visited on Sep. 10, 2009, 2008, 2 pages. |
Wound Care Technologies, “Instructions for Use. DERMAClose™ RC”, available online at <http://www.dermaclose.com/instructions.pdf>, last visited on Sep. 10, 2009, 2008, 2 pages. |
Extended European Search Report (includes Supplementary European Search Report and Search Opinion); European Patent Application No. 12732236.0, dated Jun. 29, 2015., pp. all. |
Intention to Grant; European Patent Application No. 12752239.9, dated Sep. 24, 2015., pp. all. |
Aarabi et al., “Mechanical Load Initiates Hypertrophic Scar Formation Through Decreased Cellular Apoptosis”, The FASEB Journal, vol. 21, Oct. 2007, pp. 3250-3261. |
Al-Attar et al., “Keloid Pathogenesis and Treatment”, Plastic and Reconstructive Surgery, vol. 117, No. 1, Jan. 2006, pp. 286-300. |
Angelini et al., “Comparative Study of Leg Wound Skin Closure in Coronary Artery Bypass Graft Operations”, Thorax, vol. 39, 1984, pp. 942-945. |
Atkinson, et al., “A Randomized, Controlled Trial to Determine the Efficacy of Paper Tape in Preventing Hypertrophic Scar Formation in Surgical Incisions that Traverse Langer's Skin Tension Lines”, Plastic and Reconstructive Surgery, vol. 116, No. 6, Nov. 2005., pp. 1648-1656. |
Bachert et al., “Probing Elastic Modulus and Depth of a Two Layer Human Skin Model with Piezoelectric Cantilevers”, Biomedical Engineering Senior Design Team, Drexel University, 2003, pp. 1-27. |
Berman et al., “Keloid and Hypertrophic Scar”, available online at <http://www.emedicine.com/DERM/topic205.htm>, last visited on Nov. 19, 2007, 23 pages. |
Bunker, Timothy D., “Problems with the Use of Op-Site Sutureless Skin Closures in Orthopaedic Procedures”, Annals of the Royal College of Surgeons of England, vol. 65, 1983, pp. 260-262. |
Burd et al., “Hypertrophic Response and Keloid Diathesis: Two Very Different Forms of Scar”, Plastic and Reconstructive Surgery, vol. 116, No. 7, Dec. 2005, pp. 150e-157e. |
Chen et al., “Prospective Study Comparing Wounds Closed with Tape with Sutured Wounds in Colorectal Surgery,”, Arch. Surg., vol. 136, Jul. 2001, pp. 801-803. |
Davison et al. “Ineffective Treatment of Keloids with Interferon Alpha-2b”, Plastic and Reconstructive Surgery, vol. 117, No. 1, Jan. 2006, pp. 247-252. |
Escoffier et al., “Age-Related Mechanical Properties of Human Skin: An in Vivo Study”, The Journal of Investigate Dermatology, vol. 93, No. 3, Sep. 1989, pp. 353-357. |
Evans et al., “Measuring the Mechanical Properties of Human Skin in vivo Using Digital Image Correlation and Finite Element Modelling”, J. Strain Analysis, vol. 44, 2009, pp. 337-345. |
Fairclough et al., “The Use of Sterile Adhesive Tape in the Closure of Arthroscopic Puncture Wounds: A Comparison with a Single Layer Nylon Closu”, Annals of the Royal College of Surgeons of England, vol. 69, 1987, pp. 140-141. |
Gorney, Mark, “Scar: The Trigger to the Claim”, The American Society of Plastic Surgeons, vol. 117, No. 3, 2006, pp. 1036-1037. |
Hof et al., “Comparing Silicone Pressure-Sensitive Adhesives to Silicone Gels for Transdermal Drug Delivery”, Presented at 33 Annual Meeting and Exposition to the Controlled Release Society, Vienna, Austria, Jul. 22-26, 2006, 7 pages. |
Koval et al., “Tape Blisters Following Hip Surgery, A Prospective Randomized Study of Two Types of Tape”, The Journal of Bone and Joint Surgery, vol. 85-A, No. 10, Oct. 2003, pp. 1884-1887. |
Kuo et al., “Prospective, Randomized, Blinded Study of a New Wound Closure Film Versus Cutaneous Suture for Surgical Wound Closure”, Dermatologic Surgery, vol. 32, No. 5, May 2006, pp. 676-681. |
Mustoe et al., “A Randomized, Controlled Trial to Determine the Efficacy of Paper Tape in Preventing Hypertrophic Scar Formation in Surgical Incisions that Traverse Langer's Skin Tension Lines”, Plastic and Reconstructive Surgery, Nov. 2005., pp. 1657-1658. |
Nahabedian, Maurice Y., “Scar Wars: Optimizing Outcomes with Reduction Mammaplasty”, Plastic and Reconstructive Surgery, vol. 116, No. 7, Dec. 2005, pp. 2026-2029. |
O'Brien et al., “Silicon Gel Sheeting for Preventing and Treating Hypertrophic and Keloid Scars (Review)”, The Cochrane Collaboration, 2009, pp. 1-47. |
Pitcher, David, “Sutureless Skin Closure for Pacemaker Implantation: Comparison with Subcuticular Suture”, Postgraduate Medical Journal, vol. 59, Feb. 1983, pp. 83-85. |
Shirado et al., “Realization of Human Skin-Like Texture by Emulating Surface Shape Pattern and Elastic Structure”, Presented at Symposium on Haptic Interfaces for Virtual Environment and Teleoperator Systems, Mar. 25-26, 2006, Alexandria, VA, pp. 295-296. |
Sullivan et al., “Acute Wound Care”, Chapter 7 in ACS Surgery: Principles and Practice, 2007, pp. 1-24. |
Teot, Luc, “Scar Evaluation and Management: Recommendations”, European Tissue Repair Society, Scar Control I. ETRS—Bulletin 12.1 & 2, available online at <http://www.etrs.org/bulletin12_1/section11.php>, last visisted on Nov. 30, 2007, 13 pages. |
Vaughan et al., “Optimal Closure of Surgical Wounds in Forefoot Surgery: Are Adhesive Strips Beneficial?”, Acta Orthop. Belg., vol. 72, No. 6, 2006, pp. 731-733. |
Vowden, Kathryn, “Wound Management, Policy and Resource Pack”, Bradford Teaching Hospitals NHS Foundation Trust, Mar. 2003, pp. 1-72. |
Watson et al., “Op-Site Skin Closure: A Comparison with Subcuticular and Interrupted Sutures,”, Annals of the Royal College of Surgeons of England, vol. 65, 1983, pp. 83-84. |
Webster et al., “Closure of Abdominal Wounds by Adhesive Strips: A Clinical Trial,”, British Medical Journal, vol. 20, Sep. 20, 1975, pp. 696-697. |
Westaby, S., “Evaluation of a New Product for Sutureless Skin Closure”, Annals of the Royal College of Surgeons of England, vol. 62, 1980, pp. 129-132. |
Number | Date | Country | |
---|---|---|---|
20190015255 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
61605717 | Mar 2012 | US | |
61476163 | Apr 2011 | US | |
61448809 | Mar 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13411443 | Mar 2012 | US |
Child | 16026895 | US |